The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

The deacetylase sirtuin 1 (Sirt1) exerts beneficial effects on lipid metabolism, but its roles in plasma LDL-cholesterol regulation and atherosclerosis are controversial. Thus, we applied the pharmacological Sirt1 activator SRT3025 in a mouse model of atherosclerosis and in hepatocyte culture. Apoli...

Full description

Saved in:

Bibliographic Details
Published in:	European heart journal Vol. 36; no. 1; pp. 51 - 59
Main Authors:	Miranda, Melroy X, van Tits, Lambertus J, Lohmann, Christine, Arsiwala, Tasneem, Winnik, Stephan, Tailleux, Anne, Stein, Sokrates, Gomes, Ana P, Suri, Vipin, Ellis, James L, Lutz, Thomas A, Hottiger, Michael O, Sinclair, David A, Auwerx, Johan, Schoonjans, Kristina, Staels, Bart, Lüscher, Thomas F, Matter, Christian M
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 01-01-2015
Series:	Fast Track
Subjects:	Anilides - pharmacology Animals Anticholesteremic Agents - pharmacology Apolipoproteins E - deficiency Arteriosclerosis - prevention & control Cells, Cultured Cholesterol, LDL - metabolism Enzyme Inhibitors - pharmacology Hepatocytes - drug effects Hepatocytes - metabolism In Vitro Techniques Male Mice, Inbred C57BL Proprotein Convertase 9 Proprotein Convertases - secretion Receptors, LDL - drug effects Receptors, LDL - metabolism RNA, Messenger - metabolism Serine Endopeptidases - secretion Sirtuin 1 - metabolism Thiazoles - pharmacology Track Basic Science Pcsk9 Atherogenesis LDL-cholesterol Sirt1 LDL receptor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!